Singapore, October 5, 2023 – Update on Detection of Detection of Existing Influenza A Variant
Credo Diagnostics Biomedical Pte. Ltd. is committed to the post-market monitoring of the
reliability of our assays. We have performed nucleotide analysis using the BLASTn method comparing primers and probes of the assays involving influenza A virus detection to all sequences listed in NCBI Virus, GISAID and BV-BRC up till October 2nd, 2023.
We are pleased to announce that the VitaPCR™ system is capable of detecting the influenza A variants including H5N1, H5N6 and H9N2 and our analysis has confirmed that the performance of our influenza detection assays* are not impacted by the variants.
*The influenza detection assays include:
- VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay (PCRAE0128)
- VitaPCR™ Flu A&B Assay (PCRAE0103)
- VitaPCR™ Flu/RSV Assay (PCRAE0106)
For more information, contact us at service@credodxbiomed.com.
